Blur is a technology company.
Blur has raised $11.0M across 1 funding round.
Blur has raised $11.0M in total across 1 funding round.
Blur Product Development is a medical device design, engineering, and contract manufacturing firm that develops and manufactures innovative medical devices for large OEMs and startups.[1][2] It offers end-to-end services including industrial design, mechanical/electrical/software engineering, in-house prototyping, testing, and ISO 13485-certified manufacturing, addressing complex regulatory and technical challenges to bring devices to market efficiently.[1][2] With $5.4 million in revenue and 56 employees based in Cary, North Carolina, Blur solves critical problems in medical product innovation by combining creative design, engineering expertise, and real-world constraints like FDA submissions.[1][2]
The company serves medical device startups needing rapid prototyping and traction, as well as established OEMs requiring scalable manufacturing, demonstrating strong growth momentum through its full-service model and startup-friendly culture.[2]
Founded in 2014, Blur Product Development emerged to fill gaps in medical device development, offering a one-stop shop from concept to production.[1] Located at 170 Weston Oaks Ct, Cary, North Carolina, the firm was built by experienced professionals in engineering, design controls, regulatory affairs, and manufacturing, drawing from real-world expertise to hustle projects forward.[1][2] Early traction likely stemmed from its in-house capabilities—like a prototyping lab, machine shop, and human factors lab—enabling quick iterations for clients facing tight timelines and regulatory hurdles, evolving into a partner for both nascent ideas and final market pushes.[1][2]
Blur rides the wave of advancing medtech innovation, where aging populations, personalized medicine, and post-pandemic supply chain resilience demand faster, compliant device development.[1][2] Timing is ideal amid rising demand for minimally invasive devices and digital health hardware, with market forces like FDA modernization and global OEM outsourcing favoring integrated firms like Blur over siloed providers.[1][2] It influences the ecosystem by enabling startups to prototype and scale quickly, fostering a vibrant medtech pipeline while helping OEMs cut time-to-market, ultimately democratizing access to cutting-edge medical hardware.[2]
Blur is poised for expansion as medtech investments surge, potentially growing via partnerships in AI-integrated devices, wearables, and biotech hardware. Trends like regulatory streamlining and 3D-printed prototyping will amplify its in-house strengths, while ecosystem influence could evolve through acquisitions or expanded ISO-certified capacity. As a nimble player in a consolidating field, Blur's hustle positions it to capture more OEM work, tying back to its core mission of urgently bridging innovation gaps in medical devices.[1][2]
Blur has raised $11.0M in total across 1 funding round.
Blur's investors include ParaFi Capital, Stani Kulechov, Tyler Scott Ward.
Blur has raised $11.0M across 1 funding round. Most recently, it raised $11.0M Seed in March 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2022 | $11.0M Seed | ParaFi Capital, Stani Kulechov, Tyler Scott Ward |